GNMK Related Analyst Ratings
-
Cowen Starts GenMark Diagnostics (GNMK) at Outperform
-
Canaccord Genuity Lifts PT on GenMark Diagnostics (GNMK) to $18
-
Canaccord Genuity Positive on GenMark Diagnostics (GNMK)
-
Canaccord Genuity Maintains a 'Buy' on GenMark Diagnostics (GNMK); Q2 Preview: Expecting Really Good Numbers
-
JPMorgan Starts GenMark Diagnostics (GNMK) at Overweight
-
Canaccord Genuity Reiterates a 'Buy' on GenMark Diagnostics (GNMK); Secondary Completed
-
Canaccord Genuity Raises 2012 Estimates on GenMark Diagnostics (GNMK); Sales Force Expansion & Improved Lab Utilization
-
Canaccord Genuity on Life Sciences/Biomedical Devices & Services: Pipelines To Lead Way Through Q1
-
Canaccord Genuity Reiterates a 'Buy' on GenMark Diagnostics (GNMK); Opportunities Hold Promise
-
Canaccord Genuity Reiterates a 'Buy' on GenMark Diagnostics (GNMK); Positive on New CFO & Deal with PerkinElmer (PKI)
-
Canaccord Genuity Reiterates a 'Buy' on GenMark Diagnostics (GNMK); Pipeline Looking Good
-
Canaccord Genuity Reiterates a 'Buy' on GenMark Diagnostics (GNMK); XT-8 Placements Lead Again
-
Canaccord Genuity Reiterates a 'Buy' on GenMark Diagnostics (GNMK); Comfort Level Improving; Raise PT
-
Canaccord Genuity on Life Sciences: Biomedical Devices and Services - Japan Crisis: What Is The Impact on Diagnostic Companies?
-
Canaccord Genuity Reiterates a 'Buy' on GenMark Diagnostics (GNMK); XT-8 Placements Paved the Way, Look for Continuation in 2011
-
UPDATE - Canaccord Genuity Initiates Coverage on GenMark Diagnostics (GNMK) with a Buy; Addressing Key Needs of Laboratories
-
Canaccord Genuity Starts GenMark Diagnostics (GNMK) at Buy
-
ThinkEquity Initiates Coverage on GenMark Diagnostics (GNMK) with a Buy
-
Piper Jaffray Starts GenMark (GNMK) at Overweight, $8 Price Target
-
William Blair Initiates Coverage on GenMark Diagnostics (GNMK) with an Outperform
Back to GNMK Stock Lookup
